Tuyo Health review

Tuyo Health offers a more involved support package than medication delivery alone, with quarterly laboratory services, provider messaging and habit-tracking tools described for its compounded weight-care plans. Its dedicated semaglutide page advertises a starting $155 monthly amount without a separate membership. The challenge is reconciling several official descriptions before relying on a total: tirzepatide appears at both $235 and $279, the general FAQ allows higher-dose charges, and branded medicines follow a different fee arrangement. Cancellation wording also differs between the FAQ and detailed terms. Those issues do not establish that care is unavailable, but they do mean a prospective patient needs a written quote and processing deadline before authorizing a recurring payment. We assess the published program rather than claiming firsthand treatment or verified outcomes.

Tuyo is a wider telehealth platform offering weight management alongside primary care and other services. Its terms identify Tuyo Health and affiliated Revell Health clinical entities, while the public FAQ lists multiple pharmacy contacts. This provides some organizational context, but the specific prescriber and pharmacy must still be established for an individual treatment. The FAQ lists 20 service states rather than claiming that every patient nationwide can enroll. A state list on a general platform page also does not guarantee that every treatment, formulation or pharmacy can serve the same person. Confirm eligibility using the state in which the patient will physically receive care. The weight program describes both compounded and branded medicines, which require separate cost and access discussions. A patient who wants insurance to help pay for a branded prescription should not assume that the cash-pay compounded plan’s included-services statement describes that arrangement too. The billing and pharmacy route should be clear before comparing monthly totals.

The semaglutide page describes an online health assessment followed by a personalized plan and continued provider support. Depending on the state, it says review can involve a video appointment or health information with a full-body photo. That is a description of possible review methods, not a reason to withhold a relevant medical history or assume that a prescription can be obtained without clinical questions. Tuyo describes on-demand messaging, dose adjustments, weekly support groups and tracking tools. Ask which support activities are included in the selected plan and how quickly a clinician responds when symptoms occur. The offer also includes quarterly labs, but patients should identify the specific tests, collection method and any outside laboratory responsibility before enrollment. A regular testing promise is most useful when someone explains how the results affect treatment. For a transfer, provide the current prescription and recent dose history so the clinician can assess continuity. A familiar molecule name alone is insufficient to establish equivalence between the old and new concentration or instructions.

The dedicated compounded pages list $155 for semaglutide and $235 for tirzepatide, while the main comparison section lists tirzepatide from $279. The same comparison says costs vary by dose, and the general FAQ permits additional charges for higher-dose prescriptions. We therefore do not treat a starting advertisement as an unconditional all-dose monthly floor. The branded section lists separate cash examples plus a $99 membership, and its $25 promotional headlines are not a universal drug-and-care price. Cancellation needs similar attention: the FAQ says it is immediate with no future billing, but the detailed terms require cancellation at least two days before the renewal processing date, allow the first renewal to occur early and permit subsequent processing up to two days early for operational reasons. The terms also exclude refunds for partially used periods. Ask for the actual processing date and confirmation that a submitted cancellation stops the next charge. If pausing, note the automatic resumption date so a temporary break does not produce an unexpected renewal. A patient comparing branded and compounded pathways should ask Tuyo for two separate written estimates using the same follow-up period. Each estimate should identify the care fee, prescription source, laboratory services and any dose-dependent charge. That prevents a low pharmacy copay on one pathway from being compared directly with a cash bundle on another without the additional membership and eligibility conditions.

Tuyo explicitly states that compounded semaglutide and tirzepatide are not FDA-approved and are distinct from brand-name medicines. That is a useful disclosure, but it does not resolve why a particular compounded formulation is clinically appropriate for the patient. Ask for the complete preparation, pharmacy, strength and prescribing rationale. The platform discusses lower-BMI and microdosing pathways in its general eligibility copy; those descriptions should not be treated as established obesity indications or proof that a low-dose plan has the same evidence as approved treatment. A patient’s goals, medical history and the exact proposed regimen should drive that discussion. Published average first-month weight-loss claims are also not individual predictions, and the public pages do not provide enough methodological detail to independently evaluate those figures. Tuyo’s strongest features are the stated laboratory and support services. Its key limitations are inconsistent price and cancellation descriptions, making an individualized clinical and billing explanation particularly important before any long-term purchase.